<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30364">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02711423</url>
  </required_header>
  <id_info>
    <org_study_id>BP30042</org_study_id>
    <secondary_id>2015-005132-17</secondary_id>
    <nct_id>NCT02711423</nct_id>
  </id_info>
  <brief_title>A Single-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Gantenerumab Following Subcutaneous (SC) Administration in Healthy Volunteers</brief_title>
  <official_title>A Single-Center, Randomized, Investigator/Subject-Blind Single-Ascending Dose, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Gantenerumab Following SC Administration in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This two-part study is designed to assess the safety, tolerability, and PK of gantenerumab
      in healthy volunteers. Part I (dose escalation) will randomly assign participants to receive
      a single blinded SC dose of gantenerumab or placebo. Part II (PK extension) will randomly
      assign participants to receive a single open-label SC dose of ganenerumab at different dose
      levels according to safety assessments from Part I.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with adverse events (AEs)</measure>
    <time_frame>Up to 12 weeks (from Baseline to Day 85 +/- 5 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of gantenerumab</measure>
    <time_frame>Predose (0 hours) and 1, 6, and 12 hours from single dose administration; once daily from Days 2 to 10; and once daily on Days 12, 15, 21, 29, 43, 64, and 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC) of gantenerumab</measure>
    <time_frame>Predose (0 hours) and 1, 6, and 12 hours from single dose administration; once daily from Days 2 to 10; and once daily on Days 12, 15, 21, 29, 43, 64, and 85</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Part I (Dose Escalation): Gantenerumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single SC dose of gantenerumab on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part I (Dose Escalation): Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a single SC dose of matching placebo on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II (PK Extension): Gantenerumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single SC dose of gantenerumab on Day 1. The dose range will be determined by safety and tolerability data collected from Part I.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gantenerumab</intervention_name>
    <description>Gantenerumab will be supplied as a high-concentration liquid formulation for SC injection into the abdomen. The single dose will be administered on Day 1.</description>
    <arm_group_label>Part I (Dose Escalation): Gantenerumab</arm_group_label>
    <arm_group_label>Part II (PK Extension): Gantenerumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be supplied as a matching liquid formulation for SC injection into the abdomen. The single dose will be administered on Day 1.</description>
    <arm_group_label>Part I (Dose Escalation): Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males 18 to 45 years of age, inclusive

          -  Body mass index (BMI) 20.0 to 32.0 kilograms per meter-squared (kg/m^2), inclusive

        Exclusion Criteria:

          -  History of cancer or any clinically significant disease affecting one of the major
             organ systems

          -  Prior administration of gantenerumab

          -  Clinically significant laboratory test results

          -  Clinically relevant history of hypersensitivity or allergic reaction following
             exposure to a drug, food, or environmental agent

          -  Known hypersensitivity to gantenerumab or excipients of study drug formulation

          -  Abnormal skin condition or potentially obscuring tattoo, pigmentation, or lesion in
             the area intended for SC injection

          -  Familial history of early-onset Alzheimer's disease
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: BP30042 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global.rochegenentechtrials@roche.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 14, 2016</lastchanged_date>
  <firstreceived_date>March 14, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
